HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Theranostics

Theranostics is a rapidly evolving field at the intersection of diagnostics and therapeutics, aiming to integrate diagnostic tools and therapeutic interventions into a unified approach for personalized medicine. The term "theranostics" is derived from combining "therapy" and "diagnostics," reflecting the dual purpose of these strategies. The core principle of theranostics is to tailor medical treatments to individual patients based on their unique characteristics, such as genetic makeup or molecular profiles. This approach allows for more precise and targeted therapies, improving treatment efficacy while minimizing side effects. In theranostics, molecular imaging plays a pivotal role, enabling the visualization and characterization of disease processes at the molecular and cellular levels. Techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are employed to identify specific biomarkers associated with diseases, aiding in early diagnosis and treatment planning.

Additionally, theranostic agents often include radioisotopes or nanoparticles that not only allow for imaging but also deliver therapeutic payloads directly to the target site. For example, radiolabeled peptides or antibodies can serve both diagnostic and therapeutic purposes in oncology by selectively targeting cancer cells. The applications of theranostics extend across various medical specialties, including oncology, neurology, and cardiology. In cancer theranostics, radionuclide therapies like peptide receptor radionuclide therapy (PRRT) utilize radiolabeled compounds to target and destroy cancer cells. As the field continues to advance, the development of novel theranostic agents, improved imaging technologies, and the integration of artificial intelligence for data analysis hold promise for further enhancing the precision and effectiveness of personalized medicine. Theranostics represents a paradigm shift in healthcare, emphasizing a patient-centric approach that combines diagnostics and therapeutics to optimize outcomes and improve the overall quality of medical care.

Committee Members
Speaker at International Conference on Clinical & Translational Oncology 2026 - Yan Leyfman

Yan Leyfman

NYP- Meyer Cancer Center, United States
Speaker at International Conference on Clinical & Translational Oncology 2026 - Rajvir Dahiya

Rajvir Dahiya

University of California San Francisco, United States
Speaker at International Conference on Clinical & Translational Oncology 2026 - Jianhua Luo

Jianhua Luo

University of Pittsburgh School of Medicine, United States
ICTO 2026 Speakers
Speaker at International Conference on Clinical & Translational Oncology 2026 - Pietro Salvatori

Pietro Salvatori

Formerly, Humanitas San Pio X Hospital, Italy
Speaker at International Conference on Clinical & Translational Oncology 2026 - Sergey Suchkov

Sergey Suchkov

N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Speaker at International Conference on Clinical & Translational Oncology 2026 - Shinya Tajima

Shinya Tajima

National Hospital Organization Shizuoka Medical Centre, Japan
Speaker at International Conference on Clinical & Translational Oncology 2026 - Nayara Delgado Andre

Nayara Delgado Andre

Federal University of São João del-Rei (UFSJ), Brazil

Submit your abstract Today

Facebook Twitter XTwitter Youtube
Watsapp